Baird Medical Investment Holdings Limited

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a leading innovator in microwave ablation (MWA) technology, is proud to announce another successful international medical exchange. On July 25, the Company hosted a delegation of 16 esteemed physicians from Malaysia for an intensive MWA training and academic program, reinforcing its commitment to advancing global medical expertise. The delegation visited the Eighth Affiliated Hospital of Sun Yat-sen University for a comprehensive program focused on the latest MWA techniques. During their visit, the Malaysian physicians observed more than eight live MWA procedures, gaining firsthand insight into the practical application of the technology in a clinical setting. Following the procedural observations, the delegation participated in a dynamic academic exchange with top thyroid experts from China. This collaborative session allowed for an in-depth discussion on best practices, emerging trends, and complex cases, fostering a rich environment for knowledge sharing. At the conclusion of the program, the participating doctors were awarded MWA certificates, recognizing their successful completion of the advanced training. Baird Medical continues to champion international collaboration, equipping medical professionals across the globe with the skills and knowledge needed to excel in the field of minimally invasive therapies and solidifying its position as a global leader in MWA technology.

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, is pleased to announce its participation in the 45th Annual Meeting of the American Association of Endocrine Surgeons (AAES), taking place from May 17-19, 2025, at the Baird Center in Milwaukee, Wisconsin. The AAES Annual Meeting, a premier academic and clinical forum, convenes leading endocrine surgeons, researchers, and innovators globally to explore advancements in endocrine surgery. For Baird Medical, this event is a key platform to showcase its latest MWA technological achievements and to foster direct engagement with healthcare professionals, thereby gaining deeper insights into the evolving needs of the medical community. At this year’s meeting, Baird Medical presented its pioneering MWA system for thyroid nodule treatment, emphasizing its benefits as a minimally invasive alternative to conventional surgery. The technology garnered considerable interest from attending surgeons, who recognized its potential to enhance patient outcomes by minimizing procedural risks, preserving thyroid function, and expediting recovery. Through substantive dialogues with clinical experts, Baird Medical acquired critical feedback on practical aspects, including patient selection, ultrasound guidance optimization, and diverse application scenarios. The insights and perspectives gathered at AAES 2025 are pivotal for shaping Baird Medical’s future clinical collaboration initiatives. By maintaining a close alignment with the requirements of surgeons and their patients, the Company remains committed to advancing its mission of delivering safer, more effective treatment solutions for thyroid and other endocrine diseases.

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a leader in Microwave Ablation (MWA) technology, recently hosted an advanced training session and academic exchange in New Orleans, reinforcing its commitment to clinical innovation and research collaboration in minimally invasive thyroid therapies. The program was led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, a leading figure in thyroid ablation and endocrine surgery. He was joined by Dr. Gregory Randolph, Professor of Otolaryngology–Head and Neck Surgery at Harvard Medical School and the Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology. Visiting Tulane as a Distinguished Professor on May 9, 2025, Dr. Randolph engaged in academic discussions with Dr. Kandil on a range of thyroid-focused topics. Following their exchange, Dr. Randolph participated in clinical observations and hands-on procedures alongside Dr. Kandil. The two experts also explored emerging technologies and discussed opportunities for future research collaboration in the field of thyroid surgery. This initiative is part of Baird Medical’s broader strategy to promote excellence in thyroid care by partnering with world-class medical leaders. Through advanced training and academic partnerships, the Company continues to support the global adoption of innovative, minimally invasive therapies.

NEW YORK, NY – April 28, 2025 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a leader in Microwave Ablation (MWA) technology, recently hosted an advanced MWA training session in New Orleans, reinforcing its commitment to expanding global expertise in minimally invasive therapies. The program, led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, provided specialized training to Dr. Shahzad Ahmad, a distinguished endocrinologist and thyroid specialist from Salt Lake City. As a founding member and Treasurer of the North American Society of Interventional Endocrinology (NASOIE), Dr. Ahmad brings extensive experience in thyroid ablation techniques. During the training, Dr. Ahmad observed four live MWA procedures, evaluating the technology's efficiency and clinical benefits. Following a hands-on session, he engaged in detailed discussions with Dr. Kandil on implementing MWA across clinical settings. Upon completion, he received a Certificate of Completion, demonstrating his proficiency in this advanced treatment modality. This initiative reflects Baird Medical’s ongoing mission to advance minimally invasive thyroid therapies through collaboration with global medical leaders. By fostering training and knowledge exchange, the company continues to drive innovation and elevate treatment standards worldwide.

New York, NY – April 14, 2025 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”) recently hosted Dr. Gary G. Tse, a distinguished interventional radiologist from UCLA Health, for an immersive clinical visit in Guangzhou, China. The visit highlighted Baird Medical’s cutting-edge microwave ablation (MWA) technology and its growing role in minimally invasive thyroid treatments. Dr. Tse observed multiple thyroid nodule ablation procedures at Sun Yat-sen University Cancer Center, gaining valuable insights into the precision and clinical efficacy of Baird Medical’s MWA system. In addition to the procedural observations, Dr. Tse participated in academic discussions with Dr. Michael Mingzhao Xing, Professor Emeritus at the Johns Hopkins University School of Medicine. Together, they explored the latest advancements and clinical outcomes in thyroid nodule management. Dr. Tse’s visit reinforces Baird Medical’s commitment to fostering partnerships with leading medical experts worldwide. As the Company continues its global expansion, it remains dedicated to enhancing the accessibility and effectiveness of minimally invasive treatments for thyroid conditions.

New York, NY – April 2, 2025 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”) proudly hosted Dr. Quan-Yang Duh, a world-renowned endocrine surgeon and Chief of Endocrine Surgery at the University of California, San Francisco (UCSF), for an in-depth clinical observation visit in Guangzhou and Shenzhen, China. During his visit, Dr. Duh closely examined the real-world application of Baird Medical’s advanced microwave ablation (MWA) technology. In Guangzhou, Dr. Duh visited several prestigious hospitals, where he observed a range of thyroid ablation cases. One particularly notable case involved a patient with bilateral thyroid nodules, including a 4 cm lesion, successfully treated using Baird Medical’s MWA system. The procedure, performed by Dr. Feng Han, a leading MWA specialist at Sun Yat-sen University Cancer Center, was executed with remarkable precision and efficiency. The patient remained fully awake and comfortable throughout, underscoring the minimally invasive nature of the procedure. “The case was highly educational,” said Dr. Duh. “Dr. Han demonstrated exceptional expertise, and the speed and accuracy of the procedure highlight both the skill of the medical team and the medical team and the sophistication of the technology.” Following the procedure, Dr. Duh engaged in in-depth academic discussions with Dr. Feng Han and Dr. Jian Hua Zhou, Chief of Interventional Radiology at Sun Yat-sen University Cancer Center, further fostering international collaboration in thyroid ablation advancements. Dr. Duh continued his visit in Shenzhen, where he observed additional MWA procedures at one of the city’s leading thyroid hospitals. He also participated in academic discussions with top specialists in the field and delivered a presentation titled “Advances in Surgical Management of Thyroid and Parathyroid Diseases.” His talk provided valuable insights into the latest developments in endocrine surgery and facilitated an in-depth exchange on the growing role of microwave ablation in thyroid treatment, particularly its integration with surgical approaches. “We are honored to facilitate these global academic exchanges and showcase the clinical impact of our MWA technology,” said Haimei Wu, Chairwoman of Baird Medic

NEW YORK, March 31, 2025 -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company") proudly announces the successful utilization of its advanced microwave ablation (MWA) technology in two recent endocrine procedures. These procedures were performed by Dr. Saka Kazeem, MD, a distinguished endocrinologist with over 30 years of clinical experience. Using Baird Medical's MWA system for the first time, Dr. Kazeem praised its efficiency and seamless integration into clinical practice. "The system is both intuitive and optimizes procedure time, allowing treatments to be more streamlined without compromising patient outcomes," he stated. Baird Medical remains dedicated to driving innovation in medical technology and promoting the adoption of MWA among healthcare professionals worldwide. "Dr. Kazeem's successful experience highlights the value of our technology in improving clinical workflows and patient care," said Haimei Wu, Chairwoman of Baird Medical. "We are excited to introduce our solutions to more physicians seeking effective, minimally invasive treatment options." As the Company continues to expand its presence, Baird Medical is committed to collaborating with leading medical professionals and institutions to drive further innovation in microwave ablation technology and its applications.

New York, NY – March 3, 2025 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology, made a lasting impact at the 2025 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Lehi, Utah. As a premier gathering for experts in interventional endocrinology, NASOIE serves as a platform for advancing minimally invasive treatments for thyroid and parathyroid disorders. The event convenes top-tier clinicians and researchers to explore the latest breakthroughs in treating thyroid nodules and cancer recurrences.       Baird Medical’s presence at NASOIE 2025 drew strong engagement, with numerous physicians visiting the booth to explore the latest advancements in MWA technology. Attendees participated in hands-on thyroid phantom demonstrations, experiencing firsthand the precision, safety, and efficiency of Baird’s technology. The Company’s experts engaged in in-depth discussions, addressing key clinical considerations and providing practical insights into MWA’s role in thyroid care. Through these interactions, Baird Medical further solidified its leadership in next-generation thyroid ablation therapies, enhancing industry awareness, and reinforcing its commitment to innovation in minimally invasive treatment solutions. Baird Medical remains dedicated to advancing minimally invasive thyroid treatments by working closely with medical experts and industry leaders. The insights gained from NASOIE 2025 will help further refine the Company’s MWA technology, ensuring it meets the evolving needs of thyroid care. Through continued research, education, and collaboration, Baird Medical is committed to improving treatment options for patients with thyroid nodules and related conditions worldwide.

New York, NY – February 26, 2025 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a leading innovator in microwave ablation (MWA) technology, continues to strengthen international medical collaboration. The Company recently hosted a delegation of distinguished Bangladeshi physicians at its Guangzhou headquarters for an expert-led MWA training program, further advancing global expertise in this cutting-edge treatment modality. The delegation included Dr. MD Mofazzal Sharif, Dr. Mohammad Rezaul Haque, Dr. Alamgir A.B.M., and Dr. Mohammad Jannatul Ferdous Rubel, who participated in a comprehensive training program designed to enhance their expertise in MWA techniques. The program’s first day featured in-depth theoretical discussions and hands-on demonstrations at Baird Medical’s state-of-the-art facility, providing participants with a deeper understanding of MWA applications in clinical practice. On the second day, the delegation continued their training with a visit to Sun Yat-sen University Cancer Center, where they were warmly welcomed by Dr. Fujun Zhang, Director of the Belt and Road Training Base of the Chinese Anti-Cancer Association. The visit began with the observation of multiple live MWA procedures, including liver and lung ablations. Following these observations, the delegation engaged in a comprehensive discussion, exchanging insights and best practices with leading specialists in the field. To conclude the day, the group participated in an in-depth session on thyroid microwave ablation techniques, led by Dr. Feng Han in the hospital’s Ultrasound Department, further deepening their understanding of the latest advancements in MWA technology. “This program exemplifies our commitment to global knowledge-sharing and medical innovation,” said Haimei Wu, Chairwoman of Baird Medical. “By fostering cross-border collaboration, we aim to advance MWA technology and elevate patient care on a global scale.” Baird Medical remains dedicated to equipping medical professionals worldwide with cutting-edge expertise, reinforcing its role as a leader in the advancement of MWA technology.

New York, NY – February 10, 2025 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a leader in microwave ablation (MWA) technology, remains committed to advancing physician education and recently supported Dr. Hosai Todd-Hesham’s participation in a specialized MWA training program at the Columbia Thyroid Center in New York City. Led by Dr. Jennifer Kuo, Director of the Interventional Endocrinology Program and Program Director of the Endocrine Surgery Fellowship at Columbia University’s Department of Surgery, the two-day course provided in-depth instruction on MWA techniques, procedural safety, and clinical applications. The program attracted physicians from the United States and Mexico, including Dr. Hosai Todd-Hesham, an Otolaryngology specialist from Maryland ENT Associates, and Dr. Camilo González Velázquez, Associate Professor and Endocrinologist at Hospital Universitario ‘Dr. José E. González. During the hands-on training session, Dr. Hesham, under the expert guidance of Dr. Kuo, performed simulated procedures using a thyroid model. She focused on mastering device operation, enhancing ablation precision, and making real-time procedural adjustments. This structured training allowed her to systematically refine her expertise in thyroid MWA, further strengthening her skills in minimally invasive techniques. The live case observation session proved highly beneficial for the participating physicians. Through three procedures, they gained deeper insights into MWA’s preoperative planning, intraoperative techniques, and postoperative patient management. The practical nature of the training received high praise from attendees. Dr. Hesham described the experience as a solid foundation that enhanced her confidence and interest in microwave ablation technology. Dr. Velázquez emphasized the irreplaceable value of hands-on clinical experience, noting that many procedural nuances extend beyond textbook knowledge. One notable case involved the ablation of a 5cm thyroid nodule, where the patient experienced significant symptom relief and a smooth recovery, further demonstrating MWA’s precision and minimally invasive advantages in treating larger nodules. As a pioneer in microwave ablation, Baird Medical is dedicated to accelerating the adoption of innovative, minimally invasive treatments through specialized training and collaboration. By expanding its global MWA education network, the Company aims to provide physicians with standardized and compr